Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
04 mai 2023 07h00 HE
|
Optinose, Inc.
The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If...
Optinose Announces Reporting Date for First Quarter 2023 Financial Results
01 mai 2023 16h30 HE
|
Optinose, Inc.
YARDLEY, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the...
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 avr. 2023 08h00 HE
|
Optinose, Inc.
YARDLEY, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...
Optinose to Present at the Needham Virtual Healthcare Conference
12 avr. 2023 16h00 HE
|
Optinose, Inc.
YARDLEY, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
07 mars 2023 07h00 HE
|
Optinose, Inc.
Company reports fourth quarter and full year 2022 XHANCE net revenue of $20.9 million and $76.3 million Company submitted sNDA for XHANCE label expansion in February 2023 Physicians...
Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results
28 févr. 2023 16h30 HE
|
Optinose, Inc.
YARDLEY, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion
21 févr. 2023 07h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces CEO Transition and Business Update
31 janv. 2023 07h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Appoints Paul Spence as Chief Commercial Officer
15 déc. 2022 16h30 HE
|
Optinose, Inc.
YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Departure of Acting Chief Financial Officer
09 déc. 2022 08h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...